



The Digital Examiner

www.prostaidcalgary.org

265 November 2021

“Courage is not the absence of fear, but rather the judgement that something else is more important than fear .”

Ambrose Redmoon

Connect with us:

Information

Phone: 403-455-1916
info@prostaid.org

Brad Sterling
President

president@prostaid.org

Support Groups

Frank Altin
Warriors

faltin@telusplanet.net

Wives, Partners & Caregivers

info@prostaid.org

Newly Diagnosed

info@prostaid.org

Mailing Address

PROSTAID Calgary Society

PO Box 72126
RPO Glenmore Landing
Calgary, Alberta
T2V 5H9
Phone: 403-455-1916

To subscribe to The Digital Examiner

info@prostaid.org

PROSTAID Calgary is self-funded.

[Click here to help us to continue our good work by donating on-line](#)

Next General Meeting:
Tuesday, November 9th, 2021
@ 7:30 p.m., via ZOOM
“Technology Meets Healthcare - it’s going to be a good thing (mostly)”

Guest Speaker: Tom Keenan



Tom combines a deep technical knowledge with lively insights into the social and cultural aspects of technology. He was educated at Columbia University, receiving BA, M.Sc., MA and Ed.D. degrees in Philosophy, Mathe-

matics, Engineering and Education. He is a popular professor in the School of Architecture, Planning and Landscape as well as the Department of Computer Science at the University of Calgary. Tom taught Canada’s first computer crime course, in 1974, and was involved in drafting that country’s inaugural computer crime legislation.

In 2018 he became the Board Chair of the Information and Communications Technology Council of Canada (www.ictc-ctic.ca). He is also a frequent guest on radio and television programs and writes a syndicated Men’s Health column that appears in the Calgary Herald and other Postmedia newspapers.

His latest book, Technocreep: The Surrender of Privacy and the Capitalization of Intimacy dissects how technology is becoming creepy in hidden ways that are difficult for most people to understand.

SIDE BAR:

Of particular note:

- * A partnership between Country 105 and House of Cars, will award \$1000 to a deserving charity each month. If you haven’t already nominated, please go to: [Country 105+House of Cars Contest](#), and nominate PROSTAID Calgary.
- * On page two is a listing of all clinical trials currently recruiting through our friends at the Prostate Cancer Centre. Have a look to see if you qualify and considering signing up.
- * We are now actively looking for speakers for 2022. If you have a suggestion or topic of interest you would like to learn more about, please let me know.



Regards,
Dorothy

Dorothy Rodehutsors
Program Director
PROSTAID Calgary



Clinical Trials Currently Recruiting at The Prostate Cancer Centre

Sponsor	Study Drug	Patient Population
Bayer	Nubeqa (darolutamide) - Observational	Observational Study in non-metastatic castration-resistant prostate (nmCRPC) cancer patients
Janssen	1. Niraparib+Abiraterone Acetate+Prednisone VS. 2. Abiraterone Acetate+Prednisone	A Phase 3 Randomized, Placebo-controlled, Double-blind Study for the treatment of participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Janssen	1. ADT+Apalutamide (ARN-509) VS. 2. ADT+Placebo	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study for patients with high risk, localized or locally advanced PC who are candidates for radical prostatectomy
APCaRI 03	N/A. Modelling the Progression of Prostate Cancer: A Prospective Cohort Study	Patients with a prior diagnosis, advanced / high risk prostate cancer
Nanostics Inc.	N/A. Clinical Validation of ClarityDX Prostate as a reflex test to PSA to refine the prediction of clinically-significant prostate cancer	Men ages 40-75 years old, without prior diagnosis of PC, referred for biopsy
Janssen	N/A. Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer	Men with Metastatic Prostate Cancer (mCSPC) starting ADT within 6 months of enrollment. Comprises of a once-off blood sample to test for DDR mutation.
APCaRI PCO	N/A. Prostate Cancer Outcomes Global Initiative to Compare and Reduce Variation in Localised Prostate Cancer	Localised prostate cancer
Movemeber	N/A. Urine Biomarker Validation Project.	Active surveillance
Pfizer	1. Talazoparib + Enzalutamide VS. 2. placebo + Enzalutamide	Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer

If you are interested in any of these clinical trials, please contact Wilna Bower at wilna.b@prostatecancercentre.ca



Articles of Interest:

For Newly Diagnosed:

Radiotherapy or Surgery? Comparative, Qualitative Assessment of Online Patient Education Materials on Prostate Cancer

- * As multiple different treatment options are available for prostate cancer (PCa) and YouTube is commonly used as a source for medical information, we performed a systematic and comparative assessment of available videos guiding patients on their choice for the optimal treatment. An independent search for surgical therapy or radiotherapy of PCa on YouTube was performed and the 40 most viewed videos of both groups were analyzed.
- * August 2021

Sources of Information for Learning and Decision-Making in Men With Localized Prostate Cancer

- * Information seeking is essential for effective patient-centered decision-making. However, prostate cancer patients report a gap between information needed and information received. The importance of different information sources for treatment decision remains unclear.
- * October 2021

For Everyone:

Final Results of Phase I/II Trial of Fractionated Dose 177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

- * In this study, men with progressive mCRPC following at least 1 AR-pathway inhibitor (ARPI) and taxane chemo (or ineligible/refuse) were enrolled. The authors included 50 men. In terms of baseline characteristics, the median PSA was 173.8 and 35 (70%) were deemed CALGB (Halabi) poor risk. In terms of disease burden, 47 (94%) had bone metastasis, 38 (76%) had LN metastasis, 12 (24%) had lung metastasis, and 11 (22%) had liver metastasis.
- * September 2021 European Society for Medical Oncology Annual Conference (ESMO)

Taking Advantage of the Teachable Moment at Initial Diagnosis of Prostate Cancer-Results of a Pilot Randomized Controlled Trial of Supervised Exercise Training.

- * Increased physical activity (PA) levels are associated with improved prostate cancer (PCa) outcomes. Sustainable PA has been linked to improved health-related quality of life (QoL) in cancer patients. The time of diagnosis of PCa may offer a critical time point when patients might be more likely to consider lifestyle changes. This, in turn, may contribute to sustainable PA and its likely benefits.
- * October 2021

APCCC 2021: Who Needs Germline Testing – Prostate Cancer

- * The Advanced Prostate Cancer Consensus Conference 2021 virtual meeting session discussing PARP inhibitors and beyond included a presentation by Dr. Dana Rathkopf regarding who needs germline testing and what should be tested.
- * October 2021

For Care-givers & families:

Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study

- * To estimate relative and absolute PCa risks associated with BRCA1/2 mutations and to assess risk modification by age, family history, and mutation location.
- * January 2020

Impact of family history on oncological outcomes in primary therapy for localized prostate cancer patients: a systematic review and meta-analysis

- * Our aim was to evaluate the association of family history with biochemical recurrence-free survival, cancer-specific survival, and overall survival by means of a multivariate Cox regression analysis.
- * February 2021

Videos:

[The NCCN Guidelines on Androgen Deprivation Therapy in Localized Disease, Regional Disease, and Palliative Treatment](#)

- * in-depth look at the NCCN Guidelines on Prostate Cancer.
- * August 2021

[Future Research Efforts With PARP Inhibitors in Metastatic Prostate Cancer](#)

- * Kim Chi, MD, medical oncologist, BC Cancer, discusses future research directions with PARP inhibitors in metastatic prostate cancer.
- * October 2021

[Empowerment and Focus - Navigating a Terminal Prostate Cancer Diagnosis](#)

- * personal story from a father three young boys, business owner, and prostate cancer battler. Diagnosed in January of 2017 at age 43 with a Gleason 9 (4+5) Grade 5.
- * September 2021

[PROSTATE CANCER PATIENT LANGUAGE SURVEY](#)

- * Prostate Cancer Research Institute, online patient survey
- * You can help PCRI make better educational materials.

New in Our Library

Look for all the new material on the library table at our next in-person meeting.

If you require assistance in locating online resources, please contact us and someone will be happy to help.

[From our Video Library \(YouTube\):](#)

Recent additions uploaded, our speakers from the last three meetings, in case you missed them:

[Crush Your Stress - Rick Titan](#)

- Former World Wrestling Entertainment (W.W.E) Superstar "Razor" Rick Titan experienced plenty of highs and lows on his way to becoming a Transformational Speaker and Coach. He spoke to PROSTAID on techniques and approaches to dealing with stress, including a participatory meditation segment.

PROSTAID Calgary On-Line



Thank you to our Sponsors and Community Partners

